Is Aligos Therapeutics Inc (ALGS) overvalued? · rev $3.6M
Aligos Therapeutics Inc (ALGS) is a biotechnology company listed on US.
This page asks whether Aligos Therapeutics Inc (ALGS) looks expensive on cached numbers — not a short thesis.
Latest reported ALGS revenue for 2024-12-31 was $3.6M. Net income was -$131.2M. Revenue was down 41.7% from 2023-12-31 to 2024-12-31. ALGS currently screens at market cap $44.1M.
ALGS currently screens at market cap $44.1M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next ALGS 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the ALGS stock page for the full model, not this heading.
Not investment advice.